RNAZ_OUT_1 [2025-04-29 07:37:30 -0400] 6248 Bytes | 1660 tokens | Cum: 1660 tkns (20.75% of 8k)
==========================================================================

Hark! 'Tis 7:37 AM on Tue Apr 29, 2025, and TransCode Therapeutics (RNAZ) hath risen from $0.3800 unto $0.4208. Shall we hence delve into its secrets, or leave it to wander yond market unknown?

--- COMPANY PROFILE ---
Company: TransCode Therapeutics (RNAZ)
IPO: 2021-07-09 (3 Years Ago)
Market Cap: $376,601
Shares Outstanding: 23,340,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.

Here’s a list of headlines for TransCode Therapeutics:

Apr-21-25 04:37PM - TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
Apr-18-25 12:00PM - All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy
Mar-27-25 04:37PM - TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138
Mar-25-25 06:24PM - TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
Mar-23-25 11:11PM - TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Mar-14-25 08:35AM - SRC approves opening of TransCodes fourth cohort in trial of TTX-MC138
Mar-13-25 07:47AM - TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial
Feb-25-25 04:15PM - TransCode Therapeutics, Inc. Announces Results of Special Meeting
Feb-06-25 08:00AM - TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
Feb-04-25 04:15PM - TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
Jan-14-25 08:00AM - TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial
Jan-07-25 08:00AM - Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
Dec-18-24 08:00AM - TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial
Nov-29-24 04:25PM - TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
Nov-28-24 07:20AM - Transcode Therapeutics issues 21.2M shares at 37.7c in private placement
Nov-27-24 07:00AM - TransCode Therapeutics, Inc. Announces $8 Million Private Placement
Nov-26-24 07:05AM - Transcode Therapeutics announces 1-for-33 reverse stock split
Nov-25-24 07:00AM - TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
Nov-12-24 07:00AM - TransCode Therapeutics Open Letter to Shareholders
Nov-05-24 07:00AM - TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
Oct-23-24 07:00AM - TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
Oct-10-24 07:00AM - TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology

Prior AI Reports for RNAZ:
1. 2025-04-01 – Score: 10 – Target: 0.5880 – Highs: 0.6100 / 0.5750 / 0.52
companys-downward-spiral-continues-amidst-major-financial-strain
2. 2025-03-21 – Score: 10 – Target: 1.1500 – Highs: 1.6700 / 0.7700 / 0.72
transcode-therapeutics-struggles-amid-high-short-interest-and-negative-returns

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-07-23T17:26:37Z - Why Transcode Therapeutics (RNAZ) Stock Is Down 60% - Benzinga
B2 - 2024-06-10T12:07:00Z - Beat the Market Like Zacks: Goldman Sachs, Micron, Amgen in Focus
B3 - 2024-06-10T11:00:00Z - Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
B4 - 2024-05-29T13:15:00Z - TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
B5 - 2024-05-12T10:18:00Z - Successful Penny Stocks Trader Tips, 3 To Use
B6 - 2024-04-03T13:10:00Z - TransCode Therapeutics Reports 2023 Results; Provides Business Update

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for TransCode Therapeutics (RNAZ).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

RNAZ_OUT_3 [2025-04-29 07:37:31 -0400] 789 Bytes | 211 tokens | Cum: 1873 tkns (23.41% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Why Transcode Therapeutics (RNAZ) Stock Is Down 60% - Benzinga**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/24/07/39913968/why-transcode-therapeutics-rnaz-stock-is-down-60Transcode Therapeutics (RNAZ) stock is trading 62% lower after the company announced the pricing of a public offering of 10 million shares at $0.30 per share, aiming to raise $3 million. The funds will be used for product development, including clinical trials for their lead therapeutic candidate.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RNAZ_OUT_5 [2025-04-29 07:37:32 -0400] 977 Bytes | 286 tokens | Cum: 2161 tkns (27.01% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-24T17:05:54Z - 12 Health Care Stocks Moving In Thursday's Intraday Session - CERo Therapeutics Hldgs (NASDAQ:CERO),...
A2 - 2025-04-24T00:28:15Z - $RNAZ | ($RNAZ) Trading Signals (RNAZ)...
A3 - 2025-04-21T20:37:00Z - TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned ...
A4 - 2025-04-21T20:37:00Z - TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned ...
A5 - 2025-04-21T20:37:00Z - TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned ...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

RNAZ_OUT_7 [2025-04-29 07:37:32 -0400] 1181 Bytes | 348 tokens | Cum: 2511 tkns (31.39% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**12 Health Care Stocks Moving In Thursday's Intraday Session - CERo Therapeutics Hldgs (NASDAQ:CERO), BioSig Technologies (NASDAQ:BSGM)**Date: 2025-04-24Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44989024/12-health-care-stocks-moving-in-thursdays-intraday-sessionGainers CERo Therapeutics Hldgs CERO stock moved upwards by 37.6% to $1.1 during Thursday's regular session. The company's market cap stands at $5.9 million. TransCode Therapeutics RNAZ shares increased by 26.43% to $0.4. The market value of their outstanding shares is at $9.2 million. Zhengye Biotechnology ZYBT shares increased by 24.8% to $9.76. The market value of their outstanding shares is at $462.5 million. Community Health Sys CYH shares increased by 24.69% to $3.03. The market value of their outstanding shares is at $420.9 million. As pe

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RNAZ_OUT_9 [2025-04-29 07:37:33 -0400] 1181 Bytes | 344 tokens | Cum: 2857 tkns (35.71% of 8k)
==========================================================================

Showing A1 (chunk 2 of 4): r the press release, Q1 earnings came out yesterday. BioSig Technologies BSGM shares increased by 23.43% to $0.79. The market value of their outstanding shares is at $19.1 million. Jaguar Health JAGX shares moved upwards by 19.94% to $8.0. The market value of their outstanding shares is at $5.3 million. Losers NuCana NCNA shares decreased by 26.3% to $0.66 during Thursday's regular session. The company's market cap stands at $3.9 million. Intensity Therapeutics INTS shares decreased by 23.85% to $0.99. The company's market cap stands at $15.0 million. Ensysce Biosciences ENSC shares declined by 16.08% to $3.08. The company's market cap stands at $5.0 million. Metsera MTSR stock fell 15.17% to $20.0. The company's market cap stands at $2.1 billion. Catheter Precision VTAK stock declined by 12.5% to $0.28. The market value of their outstanding shares is at $2.2 million. Plus Therapeutics P

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RNAZ_OUT_11 [2025-04-29 07:37:34 -0400] 1181 Bytes | 386 tokens | Cum: 3245 tkns (40.56% of 8k)
==========================================================================

Showing A1 (chunk 3 of 4): STV shares decreased by 11.41% to $0.87. The market value of their outstanding shares is at $5.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSGMBioSig Technologies Inc$0.780021.9%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum15.59Growth84.23Quality-Value2.67Price TrendShortMediumLongOverviewCEROCERo Therapeutics Holdings Inc$1.1240.1%CYHCommunity Health Systems Inc$3.0224.2%ENSCEnsysce Biosciences Inc$3.08-16.2%INTSIntensity Therapeutics Inc$0.9900-23.9%JAGXJaguar Health Inc$8.1021.4%MTSRMetsera Inc$20.02-15.1%NCNANuCana PLC$0.6587-26.0%PSTVPlus Therapeutics Inc$0.8828-10.2%RNAZTransCode Therapeutics Inc$0.380321.1%VTAKCatheter Precision Inc$0.3038-5.06%ZYBTZhengye Biotechnology

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RNAZ_OUT_13 [2025-04-29 07:37:35 -0400] 357 Bytes | 107 tokens | Cum: 3354 tkns (41.93% of 8k)
==========================================================================

Showing A1 (chunk 4 of 4): Holding Ltd$9.8425.8%Market News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RNAZ_OUT_15 [2025-04-29 07:37:35 -0400] 1082 Bytes | 285 tokens | Cum: 3641 tkns (45.51% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-15 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

You should read the following discussion and analysis of our financial condition and results of operations together with the Fin Stmnts section of this Annual Report on Form ...

S2 - 2025-03-25 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On March 23, 2025, TransCode Therapeutics, Inc., a Delaware corporation (the Company), entered into a Placement Agency Agrmt (the Agrmt) with ThinkEquity LLC (the Placement Agent), pursuant to which the Company agree...

S3 - 2025-03-25 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On March 23, 2025, TransCode Therapeutics, Inc., a Delaware corporation (the Company), entered into a Placement Agency Agrmt (the Agrmt) with ThinkEquity LLC (the Placement Agent), pursuant to which the Company agree...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

RNAZ_OUT_17 [2025-04-29 07:37:36 -0400] 1181 Bytes | 242 tokens | Cum: 3885 tkns (48.56% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together with the Financial Statements section of this Annual Report on Form 10-K including the related notes appearing elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those set forth in the Cautionary Note Regarding Forward Looking Statements and Risk Factors sections of this Annual Report, our actual results could differ materially from the results described in or implied by the forward-looking state

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RNAZ_OUT_19 [2025-04-29 07:37:36 -0400] 1181 Bytes | 275 tokens | Cum: 4162 tkns (52.02% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): ments contained in the following discussion and analysis.

Company Overview

TransCode is a platform delivery company focused on oncology, created on the belief that cancer can be defeated through the intelligent design and effective delivery of targeted therapeutics. Our lead therapeutic candidate, TTX-MC138, targets microRNA-10b, or miRNA-10b, generally believed to be a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and several others. In 2023, we conducted a Phase 0 clinical trial intended to demonstrate quantitative delivery of radiolabeled TTX-MC138 to metastatic lesions in subjects with advanced solid tumors. We treated one patient in the Phase 0 trial. In April 2024, we received an IND Study May Proceed notification from FDA to conduct a Phase I/II clinical trial with TTX-MC138 which trial

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RNAZ_OUT_21 [2025-04-29 07:37:37 -0400] 1181 Bytes | 286 tokens | Cum: 4450 tkns (55.62% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): commenced in the third quarter 2024.

In addition to TTX-MC138, we have other solid tumor programs in the preclinical stage. One, TTX-siPDL1, is an siRNA-based modulator of programmed death-ligand 1. A second, TTX-RIGA, is an RNA-based agonist of the retinoic acid-inducible gene I, or RIG-I, targeting activation of innate immunity in the tumor microenvironment. In addition, two of our pipeline candidates are TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells, which we may seek to develop subject to available funding.

All our therapeutic candidates are designed to utilize our proprietary TTX delivery mechanism with the goal of significantly improving outcomes for cancer patients.

T

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RNAZ_OUT_23 [2025-04-29 07:37:38 -0400] 1181 Bytes | 250 tokens | Cum: 4702 tkns (58.77% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): argeted Therapeutic Delivery Background

For decades, ribonucleic acid, or RNA, has been a topic of investigation by the scientific community as a potentially attractive therapeutic modality because it can target any gene and it lends itself to rational and straightforward drug design. RNA-based therapeutics are highly selective to their targets and potentially applicable to a broad array of previously undruggable targets in the human genome. We believe that one of the major challenges to widespread use of RNA therapeutics in oncology and other indications has been the inability to deliver these molecules inside cells.

To customize the development of targeted therapeutics, we have developed a design engine that is modular at both the levels of the core nanoparticle and the therapeutic loading. The size, charge, and surface chemistry of the core iron oxide nanoparticle are designed so t

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RNAZ_OUT_25 [2025-04-29 07:37:38 -0400] 1181 Bytes | 259 tokens | Cum: 4963 tkns (62.04% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): hat it can be tuned to optimize the particles for the intended target and therapeutic load. The therapeutic load is designed to consist of synthetic oligonucleotides and other molecular moieties such as proteins, peptides, radionuclides, and small molecules that can be adapted to the specific approach being developed. The approach can range from RNA interference, or RNAi, including small interfering RNAs, antisense oligonucleotides, and non-coding RNA mimics to Pattern Recognition Receptors such as RIG-I. We believe the TTX platform can further be used for developing targeted radiolabeled therapeutics and diagnostics and other custom products targeting known and novel biomarkers and other genetic elements as they are discovered and validated.

Our TTX platform is designed to overcome extracellular and intracellular delivery issues of stability, efficiency, and immunogenicity faced by exi

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RNAZ_OUT_27 [2025-04-29 07:37:39 -0400] 790 Bytes | 173 tokens | Cum: 5138 tkns (64.22% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): sting lipid and liposomal nanoparticle platforms while optimizing targeting of and accumulation in tumors and metastases. We believe the ability to deliver targeted therapeutics inside tumors and metastases will potentially allow us to target genes and other important biomarkers for cancer treatment that have until now remained undruggable using other delivery systems.

TTX Delivery System

The therapeutic potential of RNA in oncology has remained an unrealized promise due in large part, we believe...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RNAZ_OUT_29 [2025-04-29 07:37:45 -0400] 5965 Bytes | 1575 tokens | Cum: 6715 tkns (83.94% of 8k)
==========================================================================

This is our set of metrics for TransCode Therapeutics.
Please analyze the numbers.

+-------------------+-----------------------+------------------------+--------------------------+
| Volume: 3,201,118 | Perf Month: -18.88% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+-------------------+-----------------------+------------------------+--------------------------+
| Avg Volume: 7.16M | Perf Quarter: -93.82% | Short Float: 4.95% | ROE: -490.03% |
+-------------------+-----------------------+------------------------+--------------------------+
| Rel Volume: 0.42 | Index: - | Short Ratio: 0.15 | ROI: - |
+-------------------+-----------------------+------------------------+--------------------------+
| RSI (14): 33.84 | Market Cap: 9.85M | Short Interest: 1.04M | Sales Surprise: -100.00% |
+-------------------+-----------------------+------------------------+--------------------------+
| ATR (14): 0.20 | Shs Outstand: 23.34M | Beta: 1.52 | EPS Surprise: 91.98% |
+-------------------+-----------------------+------------------------+--------------------------+
| SMA20: 4.59% | Shs Float: 20.98M | Sales Q/Q: - | P/E: - |
+-------------------+-----------------------+------------------------+--------------------------+
| SMA50: -78.14% | Inst Own: 0.78% | Sales past 5Y: 0.00% | Earnings: Mar 28 |
+-------------------+-----------------------+------------------------+--------------------------+
| SMA200: -95.45% | Insider Own: 10.11% | Employees: 7 | |
+-------------------+-----------------------+------------------------+--------------------------+
| Perf Week: 40.60% | Insider Trans: 0.00% | Debt/Eq: - | |
+-------------------+-----------------------+------------------------+--------------------------+

The next section covers any insider trading by TransCode Therapeutics officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -5190814.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.4218
Average Volume: 4032285.2
30-Day High: 0.5409
30-Day Low: 0.2725

[Detailed Financials: Q2 2024]
- Total Assets: $4,824,588.00
- Total Liabilities: $3,502,314.00
- Total Equity: $1,322,274.00
- Current Assets: $4,386,421.00
- Current Liabilities: $3,502,314.00

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: $-5,190,814.00
- Gross Profit: N/A
- Operating Income: $-5,113,916.00
- Earnings Per Share (EPS): -0.74

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-1,559,125.00

[Detailed Financials: Q1 2024]
- Total Assets: $7,290,467.00
- Total Liabilities: $2,706,172.00
- Total Equity: $4,584,295.00
- Current Assets: $6,714,022.00
- Current Liabilities: $2,706,172.00

[Income Statement: Q1 2024]
- Revenue: $0.00
- Net Income: $-3,326,812.00
- Gross Profit: N/A
- Operating Income: $-3,288,982.00
- Earnings Per Share (EPS): -0.65

[Cash Flow Statement: Q1 2024]
- Net Cash Flow: $2,146,078.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of TransCode Therapeutics (RNAZ).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about TransCode Therapeutics.

2) MARKET_SCORE[]
This conversation was initiated because RNAZ is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for RNAZ.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, RNAZ could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect RNAZ to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of TransCode Therapeutics.

11) ETHICAL_RATING[]
Rate TransCode Therapeutics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of TransCode Therapeutics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

RNAZ_IN_31 [2025-04-29 07:37:45 -0400] 126 Bytes | 29 tokens | Cum: 6955 tkns (86.94% of 8k)
==========================================================================

====================================
[2025-04-29 07:37:45] # Analysis Completed
Elapsed Time: 15.59 seconds